Symbiotec Pharmalab IPO 2026: Subscription Open from August 24 to August 27, 2026 on BSE
- August 26, 2026
- Posted by: Neeraj Pandey
- Category: IPO
Symbiotec Pharmalab IPO open Aug 24-27, 2026. BSE SME platform. Check BSE/NSE for price band and lot size.
Quick Answer
The Symbiotec Pharmalab initial public offering (IPO) is open for subscription from August 24 to August 27, 2026 on the BSE SME platform. Investors can apply through their demat accounts via ASBA or UPI payment method. For the official price band, lot size, and subscription status, check the BSE or NSE website. Grey market premium data should only be sourced from independent, unofficial trackers and treated as informal information only.
The Symbiotec Pharmalab IPO has opened for public subscription on August 24, 2026, and will remain open until August 27, 2026. This is an SME IPO listed on the BSE SME platform. As with all SME initial public offerings, investors should check the official prospectus and BSE or NSE disclosures for the verified price band, lot size, issue size, and other key terms before applying.
The Symbiotec Pharmalab initial public offering has attracted attention from retail and non-institutional investor categories who typically participate in SME IPOs through their broker platforms using ASBA or UPI-based application methods. Today, August 26, 2026, is day 3 of the subscription period. Investors who have not yet applied should ensure they do so before August 27.
Click Here – Get Free Investment Predictions
Symbiotec Pharmalab IPO: Key Details at a Glance
| Parameter | Detail |
|---|---|
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Listing Platform | BSE SME |
| Application Mode | ASBA or UPI |
| Price Band | Check BSE (bseindia.com) for official band |
| Lot Size | Check BSE (bseindia.com) for official lot size |
| Category Reservations | QIB, NII, Retail (per SEBI SME norms) |
About Symbiotec Pharmalab
Symbiotec Pharmalab is a pharma manufacturer seeking a BSE SME listing through this initial public offering for capacity expansion and general corporate purposes.
India’s generic pharma sector is globally competitive. Review the product portfolio, manufacturing regulatory status, and client base in the official Red Herring Prospectus.
How to Apply for the Symbiotec Pharmalab IPO
Applying for the Symbiotec Pharmalab initial public offering is straightforward if you have an active demat account with a SEBI-registered broker. Log into your broker’s trading app or platform, navigate to the IPO section, find the Symbiotec Pharmalab IPO listing, enter the number of lots you wish to apply for, and submit your application using ASBA (for bank account deduction) or the UPI method (for immediate mandate approval via your UPI app). Ensure your bank account has sufficient funds to cover the full application amount before submitting.
Retail investors can apply for up to a maximum bid value of Rs 2 lakh per application. Applications above this threshold fall in the Non-Institutional Investor (NII) category. Ensure your UPI mandate request is approved before the subscription close time on August 27. An unconfirmed UPI mandate will result in application rejection.
Univest does not publish grey market premium figures. The grey market premium is an unofficial and unregulated indicator collected informally outside the stock exchanges. It is not published, verified, or endorsed by SEBI, NSE, or BSE, and can vary widely between trackers. To check the latest grey market premium for this initial public offering, you may visit independent trackers such as InvestorGain.com or Chittorgarh.com. Always treat this data as informal and supplementary only.
Track Symbiotec Pharmalab IPO and All Active IPOs on the Univest Screener
Risks of Investing in SME IPOs
SME IPOs come with specific risks that retail investors should consider. These companies are typically smaller in scale and have shorter operating histories compared to mainboard companies. Liquidity on SME platforms is generally lower, meaning the bid-ask spread can be wide and exiting positions may take longer. Post-listing lock-in periods for promoters and anchor investors also affect how freely shares trade in the secondary market.
The subscription status, listing premium, and post-listing performance of SME IPOs vary widely. Investors should focus on the company’s revenue growth, profitability, debt levels, promoter background, and use of IPO proceeds as outlined in the Red Herring Prospectus available on the SEBI and BSE websites. Always consult a SEBI-registered advisor before investing in any SME IPO.
Where to Track Symbiotec Pharmalab IPO Subscription Status
The official subscription data for Symbiotec Pharmalab IPO is published on the BSE website (bseindia.com) under the IPO section. NSE (nseindia.com) also publishes subscription data for IPOs listed on its platform. You can check how many times each investor category (Retail, NII, QIB) has subscribed as the window progresses. Subscription status is typically updated multiple times each day during the open period.
Conclusion
The Symbiotec Pharmalab IPO is open for subscription until August 27, 2026, on the BSE SME platform. Investors interested in this initial public offering should read the Red Herring Prospectus carefully, check the official price band and lot size on BSE or NSE, and apply through their registered broker before the close time. Grey market premium data should be treated as informal and unofficial. Always consult a SEBI-registered financial advisor before making any investment decision in SME IPOs.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Download the Univest iOS App or Univest Android App to track Symbiotec Pharmalab IPO subscription status and all active IPOs in one place.
Frequently Asked Questions
What is the Symbiotec Pharmalab IPO subscription date?
Ans. The Symbiotec Pharmalab IPO is open for subscription from August 24 to August 27, 2026. Investors must bid within this window through ASBA or UPI mode via their broker or bank platforms.
How to apply for the Symbiotec Pharmalab IPO?
Ans. To apply for the Symbiotec Pharmalab IPO, log into your demat account with your broker, go to the IPO section, search for Symbiotec Pharmalab, enter your bid at the cut-off or a specific price within the band, and submit the application using ASBA or UPI payment. Ensure your UPI mandate is approved before the subscription closes.
What is the Symbiotec Pharmalab IPO grey market premium?
Ans. Univest does not publish grey market premium figures. The grey market premium is an unofficial and unregulated indicator not verified by SEBI, NSE, or BSE. It can vary widely between trackers and is not always accurate. To check the latest Symbiotec Pharmalab IPO grey market premium, visit independent trackers such as InvestorGain.com or Chittorgarh.com.
Where can I check the Symbiotec Pharmalab IPO subscription status?
Ans. The Symbiotec Pharmalab IPO subscription status, including how many times each investor category has subscribed, is updated on the BSE website (bseindia.com) and NSE website (nseindia.com) during and after the subscription period.
What is the Symbiotec Pharmalab IPO allotment date?
Ans. The Symbiotec Pharmalab IPO allotment date is typically announced a few days after subscription closes. Check the registrar’s website, BSE/NSE, or your broker platform for the official allotment date and status.
What is Symbiotec Pharmalab’s business?
Ans. Symbiotec Pharmalab operates in the Pharmaceutical Manufacturing sector. For complete details about the company’s financials, promoter background, and business model, refer to the Red Herring Prospectus (RHP) available on the BSE and SEBI websites.
Should I invest in the Symbiotec Pharmalab IPO?
Ans. Whether to invest in the Symbiotec Pharmalab IPO depends on your risk appetite, investment horizon, and assessment of the company’s fundamentals. SME IPOs typically carry higher risk and lower liquidity compared to mainboard listings. Always read the prospectus and consult a SEBI-registered advisor before subscribing to any IPO.
